Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/14/2021 09/15/2021 09/16/2021 09/17/2021 09/20/2021 Date
346.2(c) 343.7(c) 345.15(c) 342.9(c) 341.5 Last
1 612 828 1 941 854 1 720 278 2 521 064 1 461 471 Volume
+1.33% -0.72% +0.42% -0.65% -0.41% Change
More quotes
Estimated financial data (e)
Sales 2021 61 435 M 66 178 M 66 178 M
Net income 2021 14 639 M 15 769 M 15 769 M
Net cash position 2021 4 891 M 5 268 M 5 268 M
P/E ratio 2021 19,6x
Yield 2021 2,74%
Sales 2022 61 769 M 66 537 M 66 537 M
Net income 2022 15 430 M 16 621 M 16 621 M
Net cash position 2022 11 618 M 12 514 M 12 514 M
P/E ratio 2022 19,0x
Yield 2022 2,83%
Capitalization 299 B 322 B 322 B
EV / Sales 2021 4,78x
EV / Sales 2022 4,65x
Nbr of Employees 101 465
Free-Float 83,5%
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The... 
Sector
Pharmaceuticals
Calendar
09/21Presentation
More about the company
Ratings of Roche Holding AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about ROCHE HOLDING AG
10:17aROCHE : Booster programme welcome but plans must be in place for boosters for al..
AQ
09:56aROCHE : Says Phase III Trial of Tecentriq Showed Reduction in Lung Cancer Recurr..
MT
09:06aROCHE : New Phase III Data Support the Benefit of Genentech's Tecentriq in Early..
BU
09:05aROCHE : New Phase III data support the benefit of Roche's Tecentriq in early-sta..
AQ
09:05aPRESS RELEASE : New Phase III data support the -2-
DJ
09:05aPRESS RELEASE : New Phase III data support the benefit of Roche's Tecentriq in e..
DJ
07:56aROCHE HOLDINGS AG : JP Morgan gives a Neutral rating
MD
06:06aBiogen, Samsung Bioepis Get FDA OK for Lucentis Biosimilar
DJ
04:12aROCHE : Invitation to Roche's 3rd Quarter Sales 2021 Webinar
PU
09/17ROCHE : European Medicines Agency Recommends Roche's Lung Cancer Drug For Approv..
MT
09/17ROCHE HOLDINGS AG : JP Morgan gives a Neutral rating
MD
09/17ROCHE : receives positive CHMP opinion for Gavreto« (pralsetinib) for the treatm..
AQ
09/17PRESS RELEASE : Roche receives positive CHMP -2-
DJ
09/17PRESS RELEASE : Roche receives positive CHMP opinion for Gavreto(R) (pralsetinib..
DJ
09/17Roche Receives Positive CHMP Opinion for Gavreto« (Pralsetinib) for the Treat..
CI
More news
News in other languages on ROCHE HOLDING AG
11:47aAktien Schweiz schwach - Evergrande-Krise belastet Banken
10:24aROCHE : résultats positifs d'une étude évaluant Tecentriq
09:56aRoche affirme que l'essai de phase III du Tecentriq a montré une réduction du..
09:22aRoche präsentiert neue Daten zu Tecentriq bei Behandlung von Lungenkrebs
09:22aRoche revendique un avantage du Tecentriq contre un cancer du poumon
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 342,90 CHF
Average target price 384,23 CHF
Spread / Average Target 12,1%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG10.97%321 442
JOHNSON & JOHNSON4.68%433 701
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604
ABBVIE INC.0.54%190 378